Merck applauds VA for adopting biosimilar medicines to treat veterans
Merck is acknowledging the Department of Veterans Affairs for adopting biosimilar medications and awarding the company a national contract for its biosimilar Renflexis (infliximab-abda).
“We are pleased that VA has chosen to expand access to an important treatment option such as Renflexis for our veterans who have nobly served this country,” Patrick Magri, Merck U.S. hospital and specialty business unit senior vice president, said.
Renflexis was approved by the FDA in April 2017 as a biosimilar to Remicade (infliximab).
“VA recognizes the value biosimilars bring to the healthcare system, and the award of this contract is consistent with VA’s goal of providing quality treatment options while optimizing resources in the care of Veterans,” chief consultant for pharmacy benefits management Michael Valentino said in a statement.
Renflesix is a tumor necrosis factor blocker that is indicated for Crohn’s disease, pediatric Crohn’s diseases, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.
“We are pleased that VA has chosen to expand access to an important treatment option such as Renflexis for our veterans who have nobly served this country,” Patrick Magri, Merck U.S. hospital and specialty business unit senior vice president, said.
Renflexis was approved by the FDA in April 2017 as a biosimilar to Remicade (infliximab).
“VA recognizes the value biosimilars bring to the healthcare system, and the award of this contract is consistent with VA’s goal of providing quality treatment options while optimizing resources in the care of Veterans,” chief consultant for pharmacy benefits management Michael Valentino said in a statement.
Renflesix is a tumor necrosis factor blocker that is indicated for Crohn’s disease, pediatric Crohn’s diseases, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis.